Proactive Investors - Run By Investors For Investors

Tissue Regenix shares rise as CellRight expands on Arthrex Inc relationship with European distribution deal

The AIM-listed firm said the agreement would allow Arthrex to distribute CellRight’s proprietary ‘BioRinse’ portfolio across Europe, with an initial focus on the UK
Knee bone in leg
CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures

Shares in Tissue Regenix Group PLC (LON:TRX) were on the up in mid-morning trading Tuesday after its subsidiary, CellRight Technologies, expanded its relationship with orthopaedic solutions company Arthrex Inc with a new pan-European distribution agreement.

The AIM-listed firm, which makes devices for regenerative medicine, said the agreement would allow Arthrex to distribute CellRight’s proprietary ‘BioRinse’ portfolio across Europe, with an initial focus on the UK.

READ: New Tissue Regenix CFO to step into role earlier than anticipated

The new deal, which will become effective immediately, is an extension of a previous US distribution agreement CellRight and Arthrex signed in March.

CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures to enhance healing of defects caused by trauma or disease.

READ: Tissue Regenix’s CellRight signs multi-year distribution agreement with Arthrex Inc

Steve Couldwell, chief executive of Tissue Regenix, said the agreement would allow the company to “exploit not only our ability to import our BioRinse bone portfolio into the UK facility, but also Arthrex' expansive distribution network”.

Shares were up 2% at 7.4p.

--Adds share price--

 

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use